Sanofi Extends Cancer Ambitions With IL-2 Drug And Keytruda Combination
Seeking Cancer Blockbuster To Match Dupixent Success
Executive Summary
Sanofi is playing catch-up in oncology and hopes Synthorx’s expertise will help the group advance.
You may also be interested in...
Sanofi Upbeat On Itepekimab, Rilzabrutinib And Oral IRAK4 Protein Degrader
Sanofi outlines progress on developing a differentiated R&D pipeline in immunology, including novel ways of addressing COPD, atopic dermatitis and autoimmune disorders.
Sanofi’s Berger On Creating A Sleek R&D Engine Fit For Purpose In The 2020s
A change in direction for the French firm means a new approach to R&D. Sanofi’s global head of development and chief medical officer Dietmar Berger talked to In Vivo about what was needed to get the company’s R&D machine back on track.
ESMO: Sanofi/Regeneron’s Latecomer Anti-PD-1 Libtayo Looking Likely In NSCLC
Sanofi/Regeneron’s anti-PD-1 product Libtayo may be late to the NSCLC party but strong data from EMPOWER-Lung 1 suggest it could gain traction in the space, especially in patients with high PD-L1 expression levels.